icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Treatment with Telaprevir-based Therapy after Exposure to Peg-IFN/RBV in the REALIZE Study: Results from the Phase IIIb C219 Rollover Study
 
 
  Reported by Jules Levin
EASL April 24-28 Amsterdam 2013
 
Philippe Mathurin,1 Christoph Sarrazin,2 Henk W Reesink,3 Ola Weiland,4 Moises Diago,5 Geoffrey Dusheiko,6 Antonio Ascione,7 Ziv Ben-Ari,8 Andre Lyra,9 William Sievert,10 Michael Gschwantler,11 Tarek I Hassanien,12 Ewa Janczewska,13 Katrien Janssen,14 Don Luo,15 Anne Ghys,14 Sandra De Meyer,14 Gaston Picchio,15 Katrien de Backer,14 James Witek15 1Service Maladie de l'appareil digestif and INSERM U995, Université Lille 2, Lille, France; 2Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 3Academic Medical Center, Amsterdam, The Netherlands; 4Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden; 5Hospital General de Valencia, Valencia, Spain; 6Royal Free Hospital, London, UK; 7Centre for Liver Disease, Fatebenefratelli Hospital, Napoli, Italy; 8Sheba Medical Center, Tel Hashomer, Israel; 9Hospital São Rafael, Gastro-Hepatology, São Marcos, Brazil; 10Monash Medical Centre and Monash University, Melbourne, Australia; 11Wilhelminenspital, Vienna, Austria; 12University of California, San Diego, School of Medicine, La Jolla, CA, USA; 13Outpatients Clinic for Hepatology, Myslowice, Poland; 14Janssen Infectious Diseases, Beerse, Belgium; 15Janssen Research & Development LLC, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif